Characteristics and risk factors for antituberculosis drug-induced liver injury in a cohort of patients with cirrhosis in a tertiary referral university teaching hospital in Thailand

[1]World Health Organization. Global tuberculosis report 2015. Geneva: WHO Press; 2015.World Health OrganizationGlobal tuberculosis report 2015GenevaWHO Press2015Search in Google Scholar

[2]Thulstrup AM, Mølle I, Svendsen N, Sørensen HT. Incidence and prognosis of tuberculosis in patients with cirrhosis of the liver. A Danish nationwide population based study. Epidemiol Infect. 2000; 124:221–5.ThulstrupAMMølleISvendsenNSørensenHTIncidence and prognosis of tuberculosis in patients with cirrhosis of the liver. A Danish nationwide population based studyEpidemiol Infect2000124221510.1017/S0950268899003593Search in Google Scholar

[3]Kumar N, Kedarisetty CK, Kumar S, Khillan V, Sarin SK. Antitubercular therapy in patients with cirrhosis: Challenges and options. World J Gastroenterol. 2014; 20:5760–72.KumarNKedarisettyCKKumarSKhillanVSarinSKAntitubercular therapy in patients with cirrhosis: Challenges and optionsWorld J Gastroenterol20142057607210.3748/wjg.v20.i19.5760Search in Google Scholar

[4]Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006; 354:731–9.NavarroVJSeniorJRDrug-related hepatotoxicityN Engl J Med2006354731910.1056/NEJMra052270Search in Google Scholar

[5]Senousy BE, Belal SI, Draganov PV. Hepatotoxic effects of therapies for tuberculosis. Nat Rev Gastroenterol Hepatol. 2010; 7:543–56.SenousyBEBelalSIDraganovPVHepatotoxic effects of therapies for tuberculosisNat Rev Gastroenterol Hepatol201075435610.1038/nrgastro.2010.134Search in Google Scholar

[6]Treeprasertsuk S, Huntrakul J, Ridtitid W, Kullavanijaya P, Björnsson ES. The predictors of complications in patients with drug-induced liver injury caused by antimicrobial agents. Aliment Pharmacol Ther. 2010; 31:1200–7.TreeprasertsukSHuntrakulJRidtitidWKullavanijayaPBjörnssonESThe predictors of complications in patients with drug-induced liver injury caused by antimicrobial agentsAliment Pharmacol Ther2010311200710.1111/j.1365-2036.2010.04292.xSearch in Google Scholar

[7]Perwitasari DA, Atthobari J, Wilffert B. Pharmacogenetics of isoniazid-induced hepatotoxicity. Drug Metab Rev. 2015; 47:222–8.PerwitasariDAAtthobariJWilffertBPharmacogenetics of isoniazid-induced hepatotoxicityDrug Metab Rev201547222810.3109/03602532.2014.984070Search in Google Scholar

[8]Sobhonslidsuk A, Poovorawan K, Soonthornworasiri N, Pan-ngum W, Phaosawasdi K. The incidence, presentation, outcomes, risk of mortality and economic data of drug-induced liver injury from a national database in Thailand: a population-base study. BMC Gastroenterol. 2016; 16:135. doi:10.1186/s12876-016-0550-0.SobhonslidsukAPoovorawanKSoonthornworasiriNPan-ngumWPhaosawasdiKThe incidence, presentation, outcomes, risk of mortality and economic data of drug-induced liver injury from a national database in Thailand: a population-base studyBMC Gastroenterol20161613510.1186/s12876-016-0550-0Open DOISearch in Google Scholar

[9]Dossing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis. 1996; 77:335–40.DossingMWilckeJTAskgaardDSNyboBLiver injury during antituberculosis treatment: an 11-year studyTuber Lung Dis1996773354010.1016/S0962-8479(96)90098-2Search in Google Scholar

[10]Golemba AS, Ferreyra FG, Martearena RE, Achinelli FR, Rovai GB. Drug-induced hepatotoxicity and tuberculosis in a hospital from the Argentinian northeast: cross-sectional study. Medwave. 2015; 15:e6135. doi:10.5867/medwave.2015.04.6135.GolembaASFerreyraFGMartearenaREAchinelliFRRovaiGBDrug-induced hepatotoxicity and tuberculosis in a hospital from the Argentinian northeast: cross-sectional studyMedwave201515e613510.5867/medwave.2015.04.613526035138Open DOISearch in Google Scholar

[11]Gülbay BE, Gürkan OU, Yıldız OA, Önen ZP, Erkekol FO, Baççıoğlu A, Acıcan T. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med. 2006; 100:1834–42.GülbayBEGürkanOUYıldızOAÖnenZPErkekolFOBaççıoğluAAcıcanTSide effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosisRespir Med200610018344210.1016/j.rmed.2006.01.01416517138Search in Google Scholar

[12]Isa SE, Ebonyi AO, Shehu NY, Idoko P, Anejo-Okopi JA, Simji G, et al. Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria. Int J Mycobacteriol. 2016; 5:21–6.IsaSEEbonyiAOShehuNYIdokoPAnejo-OkopiJASimjiGAntituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, NigeriaInt J Mycobacteriol2016521610.1016/j.ijmyco.2015.10.00126927986Search in Google Scholar

[13]Saha A, Shanthi FXM, Winston AB, Das S, Kumar A, Michael JS, Balamugesh T. Prevalence of hepatotoxicity from antituberculosis therapy: a five-year experience from South India. J Prim Care Community Health. 2016; 7:171–4.SahaAShanthiFXMWinstonABDasSKumarAMichaelJSBalamugeshTPrevalence of hepatotoxicity from antituberculosis therapy: a five-year experience from South IndiaJ Prim Care Community Health20167171410.1177/2150131916642431593268627056794Search in Google Scholar

[14]Sun Q, Zhang Q, Gu J, Sun W-W, Wang P, Bai C, et al. Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study. Pharmacoepidemiol Drug Saf. 2016; 25:908–17.SunQZhangQGuJSunW-WWangPBaiCPrevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort studyPharmacoepidemiol Drug Saf2016259081710.1002/pds.398826935778Search in Google Scholar

[15]Wondwossen A, Waqtola C, Gemeda A. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: a cohort study. Int J Mycobacteriol. 2016; 5:14–20.WondwossenAWaqtolaCGemedaAIncidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: a cohort studyInt J Mycobacteriol20165142010.1016/j.ijmyco.2015.10.00226927985Search in Google Scholar

[16]Hosford JD, von Fricken ME, Lauzardo M, Chang M, Dai Y, Lyon JA, et al. Hepatotoxicity from antituberculous therapy in the elderly: a systematic review. Tuberculosis. 2015; 95:112–22.HosfordJDvon FrickenMELauzardoMChangMDaiYLyonJAHepatotoxicity from antituberculous therapy in the elderly: a systematic reviewTuberculosis2015951122210.1016/j.tube.2014.10.006464044325595441Search in Google Scholar

[17]Singla R, Sharma SK, Mohan A, Makharia G, Sreenivas V, Jha B, et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res. 2010; 132:81–6.SinglaRSharmaSKMohanAMakhariaGSreenivasVJhaBEvaluation of risk factors for antituberculosis treatment induced hepatotoxicityIndian J Med Res2010132816Search in Google Scholar

[18]Wang N-T, Huang Y-S, Lin M-H, Huang B, Perng C-L, Lin H-C. Chronic hepatitis B infection and risk of antituberculosis drug-induced liver injury: systematic review and meta-analysis. J Chin Med Assoc. 2016; 79:368–74.WangN-THuangY-SLinM-HHuangBPerngC-LLinH-CChronic hepatitis B infection and risk of antituberculosis drug-induced liver injury: systematic review and meta-analysisJ Chin Med Assoc2016793687410.1016/j.jcma.2015.12.00627032895Search in Google Scholar

[19]Park WB, Kim W, Lee KL, Yim J-J, Kim M, Jung YJ, et al. Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis. J Infect. 2010; 61:323–9.ParkWBKimWLeeKLYimJ-JKimMJungYJAntituberculosis drug-induced liver injury in chronic hepatitis and cirrhosisJ Infect201061323910.1016/j.jinf.2010.07.00920670648Search in Google Scholar

[20]Shin HJ, Lee HS, Kim YI, Lim SC, Jung JP, Ko YC, Kwon YS. Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis. Int J Tuberc Lung Dis. 2014; 18:347–51.ShinHJLeeHSKimYILimSCJungJPKoYCKwonYSHepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosisInt J Tuberc Lung Dis2014183475110.5588/ijtld.13.054524670574Search in Google Scholar

[21]Cho Y-J, Lee SM, Yoo C-G, Kim YW, Han SK, Shim Y-S, Yim J-J. Clinical characteristics of tuberculosis in patients with liver cirrhosis. Respirology. 2007; 12:401–5.ChoY-JLeeSMYooC-GKimYWHanSKShimY-SYimJ-JClinical characteristics of tuberculosis in patients with liver cirrhosisRespirology200712401510.1111/j.1440-1843.2007.01069.x17539845Search in Google Scholar

[22]Sharma P, Tyagi P, Singla V, Bansal N, Kumar A, Arora A. Clinical and biochemical profile of tuberculosis in patients with liver cirrhosis. J Clin Exp Hepatol. 2015; 5:8–13.SharmaPTyagiPSinglaVBansalNKumarAAroraAClinical and biochemical profile of tuberculosis in patients with liver cirrhosisJ Clin Exp Hepatol2015581310.1016/j.jceh.2015.01.003441519125941429Search in Google Scholar

[23]Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011; 89:806–15.AithalGPWatkinsPBAndradeRJLarreyDMolokhiaMTakikawaHCase definition and phenotype standardization in drug-induced liver injuryClin Pharmacol Ther2011898061510.1038/clpt.2011.5821544079Search in Google Scholar

[24]Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J; DILIN Study Group. Drug Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009; 32:55–68. 20FontanaRJWatkinsPBBonkovskyHLChalasaniNDavernTSerranoJRochonJDILIN Study Group. Drug Induced Liver Injury Network (DILIN) prospective study: rationale, design and conductDrug Saf20093255682010.2165/00002018-200932010-00005363794119132805Search in Google Scholar

[25]Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016; 63:e147–95.NahidPDormanSEAlipanahNBarryPMBrozekJLCattamanchiAOfficial American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosisClin Infect Dis201663e1479510.1093/cid/ciw376659085027516382Search in Google Scholar

[26]Wong W-M, Wu P-C, Yuen M-F, Cheng C-C, Yew W-W, Wong P-C, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology. 2000; 31:201–6.WongW-MWuP-CYuenM-FChengC-CYewW-WWongP-CAntituberculosis drug-related liver dysfunction in chronic hepatitis B infectionHepatology200031201610.1002/hep.51031012910613746Search in Google Scholar

[27]Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest. 1991; 99:465–71.SteeleMABurkRFDesPrezRMToxic hepatitis with isoniazid and rifampin: a meta-analysisChest1991994657110.1378/chest.99.2.4651824929Search in Google Scholar

[28]Yimer G, Gry M, Amogne W, Makonnen E, Habtewold A, Petros Z, et al. Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in Ethiopian patients. PloS ONE. 2014; 9:e94271. doi:10.1371/journal.pone.0094271.YimerGGryMAmogneWMakonnenEHabtewoldAPetrosZEvaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in Ethiopian patientsPloS ONE20149e9427110.1371/journal.pone.0094271397983324714066Open DOISearch in Google Scholar

[29]Lee BL, Wong D, Benowitz NL, Sullam PM. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther. 1993; 53:529–35.LeeBLWongDBenowitzNLSullamPMAltered patterns of drug metabolism in patients with acquired immunodeficiency syndromeClin Pharmacol Ther1993535293510.1038/clpt.1993.668491064Search in Google Scholar

[30]Naidoo S, Evans D, Jong E, Mellet K, Berhanu R. Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury. S Afr Med J. 2015; 105:393–6.NaidooSEvansDJongEMelletKBerhanuROutcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injuryS Afr Med J2015105393610.7196/SAMJ.8217Search in Google Scholar

[31]Dhiman RK, Saraswat VA, Rajekar H, Reddy C, Chawla YK. A guide to the management of tuberculosis in patients with chronic liver disease. J Clin Exp Hepatol. 2012; 2:260–70.DhimanRKSaraswatVARajekarHReddyCChawlaYKA guide to the management of tuberculosis in patients with chronic liver diseaseJ Clin Exp Hepatol201222607010.1016/j.jceh.2012.07.007394052725755442Search in Google Scholar

[32]Boeree, MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015; 191:1058–65.BoereeMJDiaconAHDawsonRNarunskyKduBois JVenterAA dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosisAm J Respir Crit Care Med201519110586510.1164/rccm.201407-1264OC25654354Search in Google Scholar

[33]Pasipanodya, JG, Gumbo T. Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. Antimicrob Agents Chemother. 2010; 54:2847–54.PasipanodyaJGGumboTClinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently usedAntimicrob Agents Chemother20105428475410.1128/AAC.01567-09289729120439617Search in Google Scholar